lead program, RBI-4000, an srRNA-based rabies vaccine, has shown protective immunity at lower doses than any mRNA or srRNA vaccine reported to date in Phase I studies. Backed by Apple Tree Partners, Replicate is building a diverse pipeline of srRNA vaccines and therapeutics supported by a proprietary, customizable viral vector library. With extensive expertise in srRNA and integrated development capabilities, the company aims to broaden the application of RNA therapies across infectious diseases, immunology, and immuno-oncology.